Hofmann Wolf Peter, Sarrazin Christoph, Kronenberger Bernd, Schönberger Barbara, Bruch Katharina, Zeuzem Stefan
Innere Medizin II, Medizinische Klinik und Poliklinik, Universität des Saarlandes, Homburg, Germany.
J Infect Dis. 2003 Mar 15;187(6):982-7. doi: 10.1086/368221. Epub 2003 Mar 6.
The hepatitis C virus (HCV) envelope 2 (E2) protein interacts with the cellular receptor CD81 in vitro. Within E2, 2 CD81-binding sites were described. E2-CD81 interaction has been shown to modulate B and T cell function. The clinical importance of mutations within the CD81-binding sites and overlapping hypervariable region 2 (HVR2) in correlation with response to antiviral treatment is unknown. Fifty-five patients infected with HCV-1b or HCV-3a underwent interferon-alpha-based treatment. The E2 gene, comprising the CD81-binding sites and HVR2, was sequenced from pretreatment serum samples. The number of mutations within CD81-binding sites was not correlated with virologic treatment response in HCV-1b- and HCV-3a-infected patients. Within HVR2, the total number of mutations was significantly higher in HCV-1b-infected patients with a sustained response to interferon-alpha-based treatment (3.9; range, 1-6) than in those with relapse (2.9; range, 1-5) or those who did not respond (2.8; range, 1-5) (P = .041). However, when the same analyses were based only on functionally nonconserved mutations, no significant differences were observed.
丙型肝炎病毒（HCV）包膜2（E2）蛋白在体外与细胞受体CD81相互作用。在E2内，已描述了2个CD81结合位点。E2与CD81的相互作用已显示可调节B细胞和T细胞功能。CD81结合位点内的突变以及与抗病毒治疗反应相关的重叠高变区2（HVR2）的临床重要性尚不清楚。55例感染HCV-1b或HCV-3a的患者接受了基于α干扰素的治疗。从治疗前血清样本中对包含CD81结合位点和HVR2的E2基因进行测序。在感染HCV-1b和HCV-3a的患者中，CD81结合位点内的突变数量与病毒学治疗反应无关。在HVR2内，对基于α干扰素的治疗有持续反应的HCV-1b感染患者的突变总数（3.9；范围1 - 6）显著高于复发患者（2.9；范围1 - 5）或无反应患者（2.8；范围1 - 5）（P = 0.041）。然而，当相同分析仅基于功能上非保守的突变时，未观察到显著差异。
